Latest Immutep News & Updates

See the latest news and media coverage for Immutep. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Immutep

Biotechnology company developing LAG-3 immunotherapies

immutep.com
Headquarters
Sydney, Australia
Company type
Public company
Number of employees
10–60

Last updated

Latest news about Immutep

In short: Immutep halted its Phase III TACTI-004 lung cancer trial due to futility, while facing a securities class action and a Nasdaq compliance notice.

Company announcements

Immutep

Immutep discontinues TACTI-004 Phase III trial

IDMC recommends halt after futility analysis; root cause under review. IMP761 Phase I advances with favorable safety. Cash at A$110.6M extends to H1 CY2028.

Unlock all announcements with a

Media coverage

Markets Insider

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

First-in-human Phase I study met its primary endpoint, demonstrating favourable safety and tolerability in healthy volunteers in the single...

Unlock all articles with a

Never miss news about Immutep

Track Immutep and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Immutep competitors & trending companies

Browse news for competitors to Immutep and other trending companies.